Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial. Lusk JB, Glover L, Soneji S, Granger CB, et al. Am Heart J 2024;276:110-114.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lusk JB, Glover L, Soneji S, Granger CB, et al. Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial. Am Heart J 2024;276:110-114.
PMID: 39182939